NCT04588428

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 192 (actual)
• Sponsor: Inovio Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This study was divided into 2 parts: Part 1- dose finding stage and Part 2- dose expansion stage.

Conditions

• Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Interventions

Type	Name	Description
DRUG	INO-4700	INO-4700 was administered ID.
DRUG	Placebo	Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.
DEVICE	CELLECTRA™ 2000	EP using the CELLECTRA™ 2000 device was administered following ID drug administration
DRUG	INO-4700	INO-4700
DEVICE	CELLECTRA™ 2000	CELLECTRA™ 2000

Timeline

• Start date: 2021-06-21
• Primary completion: 2023-01-19
• Completion: 2023-01-19
• First posted: 2020-10-19
• Last updated: 2026-01-22
• Results posted: 2026-01-22

Locations

6 sites across 3 countries: Jordan, Kenya, Lebanon

Regulatory

• FDA-regulated drug study
• FDA-regulated device study